Drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome (DIHS), is a severe cutaneous drug-induced eruption. DRESS is a potentially fatal multi-organ inflammatory disease associated with herpesvirus reactivation and subsequent onset of autoimmune diseases. Pathophysiology remains elusive and therapeutic options are limited. DRESS is triggered by long-term drug exposure and it is essential to seek and to identify the culprit drugs in the months prior to eruption. Little is known about factors that predict its occurrence and about the role of the culprit drug, and virus reactivation that trigger an inappropriate systemic immune response in DRESS patients. Interestingly, it was evidenced that at-risk individuals within a genetically restricted population shared a particular HLA loci for a specific drug but the mechanism behind it is still unknown. Understanding the genetics, risk factor, Immune cell involvement and the development of animal models, cellular and biochemical assays are essential to understand, predict, diagnose and treat this unpredictable reaction.
The goal of this research topic is to bring together articles authored by experts in the field using the latest state-of-the-art advances and insights on Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). It will provide readers with an update on current disease diagnosis, management, prognosis, immunological role and future directions on the diseases. This platform will combine the expertise of dermatologists, immunologists, cell biologists, virologist interested in DRESS.
This Research Topic will address new therapies and update on DRESS. We welcome original research articles, reviews, mini-reviews, case reports and method articles including (but not limited to) the following topics:
• Current diagnosis of DRESS and gaps in diagnostic criteria (review/ original studies)
• Advances in prediction of DRESS -including pharmacogenomics and other risk factors (review and original studies)
• Updates in prognostication of DRESS (review/ original studies)
• In vitro and in vivo tests/models which can help in identification of culprit drugs in DRESS (mini-review/ original studies/ case reports)
• Current understanding of the immunology of DRESS and its implications in diagnosis, prognostication, management (review, original studies)
• Application of state-of-the-art technologies (e.g. Single Cell RNA Sequencing) for the understanding of DRESS (review, original studies)
• Novel functional links between genomics, viral reactivation and risk factors for DRESS diagnosis and management (mini review/ original studies/ case reports)
• Treatment / management /research studies which address controversies in the management of DRESS (mini-review, original studies)
• Sequelae / complications in DRESS
Topic Editor Baptiste Janela receives financial support from Evonik. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Drug reaction with eosinophilia and systemic symptoms (DRESS), also called drug-induced hypersensitivity syndrome (DIHS), is a severe cutaneous drug-induced eruption. DRESS is a potentially fatal multi-organ inflammatory disease associated with herpesvirus reactivation and subsequent onset of autoimmune diseases. Pathophysiology remains elusive and therapeutic options are limited. DRESS is triggered by long-term drug exposure and it is essential to seek and to identify the culprit drugs in the months prior to eruption. Little is known about factors that predict its occurrence and about the role of the culprit drug, and virus reactivation that trigger an inappropriate systemic immune response in DRESS patients. Interestingly, it was evidenced that at-risk individuals within a genetically restricted population shared a particular HLA loci for a specific drug but the mechanism behind it is still unknown. Understanding the genetics, risk factor, Immune cell involvement and the development of animal models, cellular and biochemical assays are essential to understand, predict, diagnose and treat this unpredictable reaction.
The goal of this research topic is to bring together articles authored by experts in the field using the latest state-of-the-art advances and insights on Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). It will provide readers with an update on current disease diagnosis, management, prognosis, immunological role and future directions on the diseases. This platform will combine the expertise of dermatologists, immunologists, cell biologists, virologist interested in DRESS.
This Research Topic will address new therapies and update on DRESS. We welcome original research articles, reviews, mini-reviews, case reports and method articles including (but not limited to) the following topics:
• Current diagnosis of DRESS and gaps in diagnostic criteria (review/ original studies)
• Advances in prediction of DRESS -including pharmacogenomics and other risk factors (review and original studies)
• Updates in prognostication of DRESS (review/ original studies)
• In vitro and in vivo tests/models which can help in identification of culprit drugs in DRESS (mini-review/ original studies/ case reports)
• Current understanding of the immunology of DRESS and its implications in diagnosis, prognostication, management (review, original studies)
• Application of state-of-the-art technologies (e.g. Single Cell RNA Sequencing) for the understanding of DRESS (review, original studies)
• Novel functional links between genomics, viral reactivation and risk factors for DRESS diagnosis and management (mini review/ original studies/ case reports)
• Treatment / management /research studies which address controversies in the management of DRESS (mini-review, original studies)
• Sequelae / complications in DRESS
Topic Editor Baptiste Janela receives financial support from Evonik. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
